Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Helical nanoplatelet superlattices assembled from green emissive CsPbI<sub>3</sub> nanoplatelets.

Chemical communications (Cambridge, England)·2026
Same author

One-dimensional CsPbBr<sub>3</sub> superlattices with polarized and amplified spontaneous circularly polarized emissions.

Nature communications·2026
Same author

Cardiac α4β2 nicotinic receptors as a therapeutic target for fatal ventricular arrhythmias.

European heart journal·2026
Same author

A chromosome-level genome assembly of the Tristram's Bunting (Emberiza tristrami).

Scientific data·2026
Same author

Seasonal variation in activity rhythms of leopard cats (Prionailurus bengalensis), their prey and competitors in southern Anhui.

Scientific reports·2026
Same author

Navigating the trade-off: Thermal hydrolysis as a winning pretreatment for simultaneously enhancing methanogenesis and immobilizing cadmium in waste activated sludge.

Journal of hazardous materials·2026

相关实验视频

Updated: May 7, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K

心肌梗塞后的瓦伦尼克林和心室外皮:一个随机的第二阶段研究.

Yunli Shen1, Xiaogang Guo2, Chunyu Zeng3

  • 1State Key Laboratory of Cardiovascular Diseases, Department of Cardiology, and Shanghai Arrhythmia Research Center, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

Journal of the American College of Cardiology
|March 4, 2026
PubMed
概括

瓦伦尼克林显著降低了后心脏病患者的早发性心室综合体 (PVC) 和心室高心率. 这种针对心脏尼古丁乙胆受体 (nAChRs) 的新方法显示出作为一种安全的抗失律疗法的前景.

关键词:
抗心律失常疗法 抗心律失常疗法心肌梗塞的心脏病发作尼古丁酸乙胆受体是什么第二阶段临床试验.过早的心室复合体.瓦伦尼克林 (varenicline) 是一种药物.

更多相关视频

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.4K
A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts
07:56

A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts

Published on: February 17, 2023

1.4K

相关实验视频

Last Updated: May 7, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

18.2K
Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction
06:57

Ablation of Ischemic Ventricular Tachycardia Using a Multipolar Catheter and 3-dimensional Mapping System for High-density Electro-anatomical Reconstruction

Published on: January 31, 2019

15.4K
A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts
07:56

A Model of Long-Term Ventricular Fibrillation in Isolated Rat Hearts

Published on: February 17, 2023

1.4K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 传统的抗心律失常药物带来了前节律失常的风险.
  • 心脏尼古丁性乙胆受体 (nAChRs) 提供了一个新的治疗点.

研究的目的:

  • 评估瓦雷尼克林在减少心肌梗塞 (MI) 后早发性心室复合物 (PVC) 的疗效和安全性.
  • 评估瓦雷尼克林的生物位参与和抗失常性潜力.

主要方法:

  • 一个多中心,随机,双盲,安慰剂控制的第二阶段试验.
  • 118名患有频繁PVCs后MI的成年人接受了瓦伦尼克林或安慰剂45天.
  • 主要终点:24小时PVC计数的百分比变化;次要终点:响应率和非持续性心室动脉短拍 (VT) 发生率.

主要成果:

  • 与安慰剂相比,瓦伦尼克林显著减少了60.1%的PVC负担 (P = 0.001).
  • 使用瓦雷尼克林时,观察到更高的响应率 (67.8%vs30.5%) 和更低的非持续静脉瘤发病率 (20.3%vs37.3%).
  • 副作用的发生率相似,在瓦雷尼克林组中没有死亡或恶性心室节律失常.

结论:

  • 瓦伦尼克林有效地降低了PVC负担和静脉瘤发病率在后心脏病患者没有前节律不良的影响.
  • 心脏nAChRs是一个可行的抗不律性标.
  • 进一步的大规模结果试验是有必要的,以证实这些发现.